

AFFILIATIONS

Nathaniel Lizak, MBBS(Hons), Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia

René Carvajal Junco, MD; Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

Sifat Sharmin, PhD, Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia

Dana Horakova, MD, PhD; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

Eva Kubala Havrdova, MD, PhD; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

Serkan Ozakbas, MD; Izmir University of Economics, Medical Point Hospital, Konak/Izmir, Turkey; Multiple Sclerosis Research Association, Izmir Turkey

Cavit Boz, MD; Department of Neurology, KTU Medical Faculty Farabi Hospital, Trabzon, Turkey

Raed Alroughani, MD; Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait

Guillermo Izquierdo, MD; Hospital Universitario Virgen Macarena, Sevilla, Spain

Sara Eichau, MD; Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain; Institute of Biomedicine of Sevilla (IBIs), CSI, University of Seville

Anneke van der Walt, MBBS, PhD; Department of Neurology, The Alfred Hospital, Melbourne, Australia; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia

Helmut Butzkueven, MBBS, PhD; Department of Neurology, The Alfred Hospital, Melbourne, Australia; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia

Jeannette Lechner-Scott, MD, PhD; Hunter Medical Research Institute, University Newcastle, Newcastle, Australia; Hunter New England Health, John Hunter Hospital, NSW Australia

Alexandre Prat, MD, PhD; CHUM MS Center and Universite de Montreal, Montreal, Canada

Marc Girard, MD; CHUM MS Center and Universite de Montreal, Montreal, Canada

Pierre Duquette, MD; CHUM MS Center and Universite de Montreal, Montreal, Canada

Katherine Buzzard, MBBS, PhD; Department of Neurosciences, Box Hill Hospital, Melbourne, Australia; Monash University, Eastern Health Clinical School, Box Hill, Australia

Olga Skibina, MD, MBBS; Department of Neurology, Box Hill Hospital, Melbourne, Australia; Department of Neurosciences, Eastern Health Clinical School, Monash University, Melbourne, Australia; Department of Neurology, The Alfred Hospital, Melbourne, Australia

Emanuele D'Amico, MD; Medical and Surgical Sciences, Universita di Foggia, Foggia, Italy

Bassem Yamout, MD; Neurology Institute, Harley Street Medical Center, Abu Dhabi-UAE, Beirut, Lebanon; American University of Beirut Medical Center

Samia J. Khoury, MD; Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon

Pierre Grammond, MD; Service de Neurologie, CISSS Chaudière-Appalache, Lévis, Canada

Matteo Foschi, MD; Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

Andrea Surcinelli, MD; Department of Neuroscience, MS Center, Neurology Unit,, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy

Stefano Neri, BMedSc, MSc; AUSL Romagna, Department of Diagnostic Imaging,, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy

Jose E Meca-Lallana, MD, PHD; Neurology Department, Virgen de la Arrixaca Clinical University Hospital, Murcia, Spain; NICEM Cathedra. UCAM-San Antonio Catholic University, Murcia, Spain

Murat Terzi, MD; Medical Faculty, Ondokuz Mayıs University, Medichal Faculty, Department of Neurology, Samsun, Turkey, Samsun, Turkey

Yolanda Blanco, MD; Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain

Oliver Gerlach, MD; Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands, Sittard-Geleen, Netherlands; School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht 6131 BK, Netherlands

Michael Barnett, MBBS, PhD; NA, Brain and Mind Centre, Sydney, Australia

Heidi Beadnall, MBBS PhD FRACP; Brain and Mind Centre, Sydney, Australia; Neurology Department, Royal Prince Alfred Hospital, Sydney, Australia

Richard Macdonell, MD; Austin Health, Melbourne, Australia

Alasdair Coles, MD; Department of Neurology,, Addenbrooke's Hospital, Cambridge, United Kingdom; NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London (UCL) Queen Square Institute of Neurology, London, United Kingdom

William Brown, MD; Personalised Treatment Group, Cambridge Clinical MS Research Group, Department of Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, United Kingdom; Department of Neurology, Cambridge University Hospitals, Cambridge

Radek Ampapa, MD; Nemocnice Jihlava, Jihlava, Czech Republic

Nevin John, MBBS, PhD; Department of Medicine, School of Clinical Sciences,, Monash University, Melbourne, Australia; Department of Neurology, Monash Health, Clayton, Australia

Gregor Brecl Jakob, MD, PhD; Department for Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Slovenia

Inés González-Suárez, MD; Neurology, Hospital Alvaro Cunqueiro, Vigo, Spain

Suzanne Hodgkinson, MBBS, PhD; Immune tolerance laboratory Ingham Institute and Dept of Medicine, UNSW, Sydney, Australia

Julie Prevost, MD; Department of Neurology, CSSS Saint-Jérôme, Saint-Jerome, Canada

Recai Turkoglu, MD; Department of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey

Davide Maimone, MD; Centro Sclerosi Multipla, UOC Neurologia,, ARNAS Garibaldi, Catania, Italy

Riadh Gouider, MD; Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi University Hospital, Tunis, Tunisia; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia

Saloua Mrabet, MD; Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi University Hospital, Tunis, Tunisia; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia

Aysun Soysal, MD; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey; Florya Medikal Park Hospital

Jose Luis Sanchez-Menoyo, MD; Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain; Biocruces-Bizkaia Health Research Institute

Daniele Spitaleri, MD; NA, Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy

Allan G Kermode, MBBS, MD; NA, University of Western Australia, Nedlands, Australia; Personalised Medicine Centre, Health Futures Institute, Murdoch University, Perth, Australia

Marzena Fabis-Pedrini, PhD; Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital, QEII MC, University of Western Australia, Nedlands, Australia, University of Western Australia, Nedlands, Australia

William M Carroll, MBBS, MD; Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital., University of Western Australia, Nedlands, Australia

Mark Slee, MBBS, PhD; College of Medicine and Public Health,, Flinders University, Adelaide, Australia

Vincent van Pesch, MD, PhD; Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Université Catholique de Louvain

Guy Laureys, MD; Department of Neurology, University Hospital Ghent, Ghent, Belgium

Bruce Taylor, MD, PhD; Royal Hobart Hospital, Hobart, Australia; Menzies Institute for Medical Research University of Tasmania

Yi Chao Foong, MBBS (Hons), PhD; MS research flagship, Royal Hobart Hospital, Hobart, Australia; Royal Hobart Hospital, Tasmanian Health Service, Hobart, TAS, Australia; School of Translational Medicine, Monash University, Melbourne, VIC, Australia

Nikolaos Grigoriadis, MD, PhD; Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece; Faculty of Medicine, Aristotle University of Thessaloniki

Tamara Castillo-Triviño, MD; Hospital Universitario Donostia, San Sebastián, Spain

Pamela McCombe, MBBS; Department of Neurology, University of Queensland, Brisbane, Australia; University of Queensland, Australia

Abdorreza Naser Moghadasi, MD; Multiple Sclerosis Research Center, Neuroscience Institute,, Tehran University of Medical Sciences, Tehran, Iran

Elisabetta Cartechini, MD; Neurology Unit, P O Unico Macerata, ast Macerata, Macerata, Italy

Abdullah Al-Asmi, MD; College of Medicine & Health Sciences, Sultan Qaboos University, Al-Khodh, Oman

Emmanuelle Lapointe, MD; Medicine, Division of Neurology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada

Simón Cárdenas-Robledo, MD; Centro de Esclerosis Múltiple, Hospital Universitario Nacional de Colombia Bogota, Bogota, Columbia; Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia

Eduardo Aguera-Morales, MD; Department of Medicine and Surgery, University Hospital Reina Sofia, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba (IMIBIC)

Mehmet Fatih Yetkin, MD; Neurology, Erciyes University, Kayseri, Turkey

Jiwon Oh, MD; NA, St. Michael's Hospital, Toronto, Canada

Stella Hughes, MD; Royal Victoria Hospital, Belfast, United Kingdom

Orla Gray, MD; South Eastern HSC Trust, Belfast, United Kingdom

Izanne Roos, MBChB, PhD*; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia

Tomas Kalincik, MD, PhD*, PGCertBiostat; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia

On behalf of the MSBase Study Group

*These authors contributed equally to this work

DISCLOSURES

Nathaniel Lizak has received conference support from Merck and speaker honoraria from Novartis.

Sifat Sharmin has no relevant disclosures.

Dana Horakova was supported by the Charles University: Cooperatio Program in Neuroscience, by the project National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107) - Funded by the European Union – Next Generation EU, and by General University Hospital in Prague project MH CZ-DRO-VFN64165. She also received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva, as well as support for research activities from Biogen Idec.

Eva Kubala Havrdova received honoraria/research support from Biogen, Merck, Novartis, Roche, and Teva; has been member of advisory boards for Actelion, Biogen, Celgene, Merck, Novartis, Sanofi, BMS, Neuraxpharm; received honoraria/research support from Biogen, Merck, Novartis, Roche, and Teva; has been member of advisory boards for Actelion, Biogen, Celgene, Merck, Novartis, and Sanofi; and has been supported by the Czech Ministry of Education – project National Institute for Neurological Research (Programme EXCELES, ID project No LX22NPO5107) – funded by the European Union-Next Generation EU.

Serkan Ozakbas Research support from Merck. Advisory board/consultancy fees from Novartis and Roche. Speaker honoraria from ARIS and Sanovel.

Cavit Boz received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.

Raed Alroughani received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme.

Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva.

Sara Eichau have received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Janssen, Bristol-Meyers, Bayer, Sanofi Genzyme, Roche and Teva

Anneke van der Walt served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck and Roche She has received speaker's honoraria and travel support from

Novartis, Roche, and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia.

Helmut Butzkueven HB is an employee of Monash University and board member and managing director of MSBase Foundation. He has received conference travel compensation from Novartis and Merck. His institution received honoraria for talks and lectures from Merck, F. Hoffmann-La Roche Ltd, Novartis. He has received personal compensation for talks from Neuraxpharm. His institution has received compensation for activities in study steering committees, advisory boards, and discussion forums from F. Hoffmann-La Roche Ltd, Novartis, and Merck and research grants from F. Hoffmann-La Roche Ltd, Argenx, Novartis, Merck, UCB, TEVA, Medical Research Future Fund Australia, NHMRC Australia, Trish Foundation, MS Australia, and Monash University

Jeannette Lechner-Scott travel compensation from Novartis, Biogen, Roche and Merck. Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Biogen, Merck, Roche and Novartis.

Alexandre Prat has no disclosures

Marc Girard has no disclosures to declare

Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.

Katherine Buzzard received speaker honoraria and/or education support from Biogen, Teva, Novartis, Genzyme-Sanofi, Roche, Merck and Alexion; has been a member of advisory boards for Merck and Biogen.

Olga Skibina received honoraria and consulting fees from Bayer Schering , Novartis, Merck, Biogen and Genzyme

Emanuele D'Amico E.D. have participated in the Roche Steering Committee and have served on advisory boards for Merck, Sanofi, Novartis, Roche, Neuraxpharm, and Biogen

Bassem Yamout I received honoraria, consulting/speaker fees, and research grants from: Merck-Serono, Biogen, Bayer, Novartis and Sanofi

Samia J. Khoury received compensation for serving on the IDMC for Biogen

Pierre Grammond has served in advisory boards for Novartis, EMD Serono, Roche, Biogen idec, Sanofi Genzyme, Pendopharm and has received grant support from Genzyme and Roche, has received research grants for his institution from Biogen idec, Sanofi Genzyme, EMD Serono.

Matteo Foschi Dr Matteo Foschi received economic support for travel and meeting attendance from Roche, Novartis, Merck, Sanofi, Bristol-Myers and served as a scientific consultant for Roche and Novartis.

Andrea Surcinelli received travel and meeting attendance support from Novartis, Biogen, Roche, Merck, Bristol, Sanofi-Genzyme, Almirall, Piam

Stefano Neri I declare that I have no conflicts of interest or financial disclosures related to the project.

Jose E Meca-Lallana Jose E. Meca-Lallana has received honoraria as a consultant, as a chairman or lecturer in meetings and has participated in clinical trials and other research projects promoted by Alexion, Almirall, Amgen, Biogen, Bristol-Myers-Squibb, Johnson & Johnson, Juvisé, Merck, Merz Therapeutics, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi and UCB

Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.

Yolanda Blanco received speaker honoraira/consulting fees from Merck, Biogen, Roche, Brystol, Novartis, Sanofi and Sandoz.

Oliver Gerlach has no disclosures

Michael Barnett served on scientific advisory boards for Biogen, Novartis and Genzyme and has received conference travel support from Biogen and Novartis. He serves on steering committees for trials conducted by Novartis. His institution has received research support from Biogen, Merck and Novartis.

Heidi Beadnall Dr Heidi Beadnall is a Member and Deputy Chair of the Research Management Committee of MS Australia. They have received honoraria for attendance at advisory boards and travel sponsorship from Biogen-Idec, Merck-Serono, Novartis, Sanofi-Genzyme and Roche. They have received speakers honoraria from Biogen-Idec, Merck-Serono, Novartis, Sanofi-Genzyme and Roche. They have been or are currently a primary investigator for clinical trials sponsored by Biogen-Idec, Novartis and Clene Nanomedicine. Dr Beadnall has been or is a sub-investigator on research grants from Biogen-Idec, Bristol Myers Squibb, Merck-Serono, Novartis and Roche.

Richard Macdonell Prof. Richard Macdonell has received remuneration paid to his institution (Austin Health) for speaking engagements, attendance at pharmaceutical advisory boards, clinical trials, investigator led research and travel support from Biogen, Merck, Genzyme, Bayer, Roche Teva, Novartis, CSL, BMS, MedDay, Flex Pharma and Clene Pharmaceuticals

Alasdair Coles has no disclosures

William Brown reports speaking honoraria from The Corpus, Biogen and Novartis; and advisory board fees from Biogen and Intesso.

William Brown, Advanced Fellow (NIHR301728) is funded by the NIHR for this research project. This work is supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

Radek Ampapa received honoraria/research support from Biogen, Merck, Novartis, Roche, Sanofi and Teva and has participated in clinical trials by Biogen, Novartis, Teva, Merck and Sanofi.

Nevin John NAJ is a PI on MS studies funded by Novartis, Roche and Sanofi. He has received congress travel and registration reimbursement; speakers honoraria and consulting fees from Novartis & Merck. He has received speakers honoraria from Biogen.

MSBase Foundation Centre Custodian has received consulting fees, speaker honoraria, support for attending meetings and/or travel, participation on advisory board and research grants for her institution from Biogen, Novartis, Sanofi, Bristol, Roche, Almirall, Janssen, Sandoz and Merck.

Gregor Brecl Jakob received honoraria as a speaker and member of scientific advisory boards from Sanofi, Bayer, Biogen, Merck, Janssen, Novartis, Roche and Amgen.

Inés González-Suárez has no disclosures

Suzanne Hodgkinson has received consulting fees and speaker honoraria from Biogen, Novartis, Roche, Merck, and has received grants for her Institution from Biogen, Merck, Novartis, and Roche.

Julie Prevost accepted travel compensation from Novartis, Biogen, Roche, EMD Serono and speaking honoraria from Biogen, Novartis, Roche and EMD Serono

Recai Turkoglu has no disclosures

Davide Maimone received speaker honoraria for Advisory Board and travel grants from Alexion, Almirall, Bayer, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva.

Riadh Gouider Riadh Gouider has received research grant and / or advisory board honoraria from Biogen, Hikma, Merck, Roche and Sanofi.

Saloua Mrabet has received a MENACTRIMS clinical fellowship grant (2020).

Aysun Soysal has no disclosures

José Luis Sánchez-Menoyo accepted travel compensation from Novartis, Merck and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in clinical trials by Biogen, Merck and Roche

Daniele Spitaleri received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva and Merck.

Allan G Kermode Allan G Kermode has received speaker honoraria and Scientific Advisory Board fees from Alexion, Bayer, BioCSL, Biogen-Idec, Biotome, Clene Nanomedicine, Eisai, Innate Immunotherapeutics, LGpharma, Merck, Mitsubishi Tanabe Pharma, Neuraxpharm, NeuroScientific Biopharmaceuticals, Neuraxpharm, Novartis, PACTRIMS, the Professional Services Review Commonwealth of Australia, Roche, Sanofi-Aventis, Sanofi-Genzyme, and Teva. His work has received grant funding from the Trish MS Foundation, MS Australia, MS Western Australia, the MS Base Foundation, the National Health and Medical Research Council of Australia, the NMSS USA, the Perron Institute, and the Eyewall Foundation. My group has also received funding from the St. John of God Hospital Foundation.

Marzena Fabis-Pedrini Marzena Fabis-Pedrini has been supported by the Western Australian Future Health Research and Innovation Fund (Grant ID WACSOP2025/6).

William M Carroll Recipient of travel assistance and honoraria for participation in industry sponsored meetings from and provided advice to,

Bayer Schering Pharma, Biogen-Idec, Novartis, Roche, Genzyme, Sanofi-Aventis, CSL, Teva, Merck and Cellgene

Mark Slee no relevant disclosure

Vincent van Pesch VvP has received travel grants from Merck Healthcare KGaA (Darmstadt, Germany), Roche, Servier and Eisai. His institution has received research grants and/or consultancy fees from Roche, Biogen, Sanofi, Merck Healthcare KGaA (Darmstadt, Germany), Bristol Meyer Squibb, Novartis Pharma, Alexion, Amgen, Neuraxpharm and Eisai

Guy Laureys received travel and/or consultancy compensation from Sanofi-Genzyme, Roche, Teva, Merck, Novartis, Celgene, Biogen.

Yi Chao Foong received travel compensation and honoraria from Biogen and Roche, research grant support from National Health and Medical Research Council, Multiple Sclerosis Research Australia and Australian and New Zealand Association of Neurologists.

Bruce Taylor received funding for travel and speaker honoraria from Bayer Schering Pharma, CSL Australia, Biogen and Novartis, and has served on advisory boards for Biogen, Novartis, Roche and CSL Australia.

Nikolaos Grigoriadis received honoraria and travel support, Consultancy and Lecture fees, Research grants from Biogen Idec, Novartis, TEVA, Merck, Genesis Pharma, Sanofi – Genzyme, ROCHE. PD served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.

Tamara Castillo-Triviño received speaking/consulting fees and/or travel funding from Almirall, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.

Pamela McCombe received speakers fees and travel grants from Novartis, Biogen, T'évalua, Sanofi

Abdorreza Naser Moghadasi has served on scientific advisory boards, received conference travel support and/or speaker honoraria from Roche, Novartis, Genzyme, Merck and Biogen.

Elisabetta Cartechini I received travel grants from Merk Serono, Neuraxpharm, AstraZeneca and Novartis.

Abdullah Al-Asmi received personal compensation for serving as a Scientific Advisory or speaker/moderator for Novartis, Biogen, Roche, Sanofi-Genzyme, and Merck.

Emmanuelle Lapointe has received speaker fees from Abbvie, Alexion, Novartis, Biogen, EMD Serono, Sanofi-Genzyme and Roche as well as consulting fees from Alexion, Novartis, Biogen, EMD Serono, Lundbeck, Sanofi-Genzyme and Horizon

Simón Cárdenas-Robledo S.C.-R has received in the past three years travel expenses for scientific meetings from Roche, Biopas, Novartis, Merck, and Genzyme; compensation for consulting services or participation on advisory boards from Amgen, Merck, Biogen-Idec, and Novartis; lecture fees from GSK, AstraZeneca, Novartis, Merck, Lumex pharma, Thermo Fisher, Takeda; and research support from Roche and Novartis.

Eduardo Aguera-Morales has received honoraria as a speaker from Biogen, Merck, Novartis and Sanofi-Genzyme and for serving on scientific advisory boards from Novartis

Mehmet Fatih Yetkin Received travel grants and honoraria as a speaker from Alexion, Novartis, Merck, and Teva; has participated in clinical trials by Sanofi Aventis, Roche, and Novartis.

Jiwon Oh has received research funding from the MS Society of Canada, National MS Society, Brain Canada, Biogen, Roche, EMD Serono (an affiliate of Merck KGaA); and personal compensation for consulting or speaking from Alexion, Biogen, Celgene (BMS), EMD Serono (an affiliate of Merck KGaA), Novartis, Roche, and Sanofi-Genzyme.

Stella Hughes has received unrestricted educational grants or speaking honoraria from Biogen, Merck, Novartis, Roche and Sanofi Genzyme.

Orla Gray received honoraria as consultant on scientific advisory boards for Genzyme, Biogen, Merck, Roche, and Novartis; has received travel grants from Biogen, Merck, Roche, and Novartis; has participated in clinical trials by Biogen and Merck. Her institution has received research grant support from Biogen.

Izanne Roos served on scientific advisory boards, received conference travel support and/or speaker honoraria from Roche, Novartis, Merck, Neuraxpharm and Biogen.

Tomas Kalincik Tomas Kalincik served on scientific advisory boards or as a consultant for MS International Federation and World Health Organisation, Therapeutic Goods Administration, Sanofi, Neuraxpharm, BMS, Roche, Janssen, Genzyme, Novartis, Merck and Biogen, received conference travel support and/or speaker honoraria from WebMD Global, Merck, Sandoz, Novartis, Biogen, Roche, Eisai, Genzyme, Teva and BioCSL and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene, Merck and Alexion.